| dc.identifier.citation | Ghislaine Scelo, Trung N. Tran, Tham T. Le, Malin Faregås, Delbert Dorscheid, John Busby, Mona Al-Ahmad, Riyad Al-Lehebi, Alan Altraja, Aaron Beastall, Celine Bergeron, Leif Bjermer, Anne S. Bjerrum, Diana Jimena Cano-Rosales, Giorgio Walter Canonica, Victoria Carter, Jeremy Charriot, George C. Christoff, Borja G. Cosio, Eve Denton, Maria Jose Fernandez-Sanchez, João A. Fonseca, Peter G. Gibson, Celine Goh, Liam G. Heaney, Enrico Heffler, Mark Hew, Takashi Iwanaga, Rohit Katial, Mariko S. Koh, Piotr Kuna, Désirée Larenas-Linnemann, Lauri Lehtimäki, Bassam Mahboub, Neil Martin, Hisako Matsumoto, Andrew N. Menzies-Gow, Nikolaos G. Papadopoulos, Pujan Patel, Luis Perez-De-Llano, Matthew Peters, Paul E. Pfeffer, Todor A. Popov, Celeste M. Porsbjerg, Chin K. Rhee, Mohsen Sadatsafavi, Camille Taillé, Carlos.A. Torres-Duque, Ming-Ju Tsai, Charlotte S. Ulrik, John W. Upham, Anna von Bülow, Eileen Wang, Michael E. Wechsler, David B. Price, Exploring definitions and predictors of response to biologics for severe asthma, The Journal of Allergy and Clinical Immunology: In Practice, 2024, , ISSN 2213-2198, https://doi.org/10.1016/j.jaip.2024.05.016. (https://www.sciencedirect.com/science/article/pii/S2213219824005300) Abstract: Abstract: Background Biologic effectiveness is often assessed as ‘response’, a term which eludes consistent definition. Identifying those most likely to respond in real-life has proven challenging. Objective To explore definitions of biologic responders in adults with severe asthma and investigate patient characteristics associated with biologic response. Methods This was a longitudinal cohort study using data from 21 countries, which shared data with the International Severe Asthma Registry. Changes in 4 asthma outcome domains were assessed in the 1-year period pre- and post-biologic-initiation in patients with predefined level of pre-biologic impairment. Responder cut-offs were: ≥50% reduction in exacerbation rate, ≥50% reduction in long-term oral corticosteroid [LTOCS] daily dose, ≥1 category improvement in asthma control, and ≥100mL improvement in FEV1. Responders were defined using single- and multiple-domains. The association between pre-biologic characteristics and post-biologic-initiation response were examined by multivariable analysis. Results 2,210 patients were included. Responder rate ranged from 80.7% (n=566/701) for exacerbation-response to 10.6% (n=9/85) for 4-domain-response. Many responders still exhibited significant impairment post-biologic-initiation: 46.7% (n=206/441) of asthma control-responders with uncontrolled asthma pre-biologic still had incompletely-controlled disease post-biologic-initiation. Predictors of response were outcome-dependent. Lung function-responders were more likely to have higher pre-biologic FeNO (OR:1.20 for every 25ppb increase), and shorter asthma duration (OR:0.81, for every 10-year increase in duration). Higher BEC and presence of T2-related comorbidities were positively associated with higher odds of meeting LTOCS-, control- and lung function-responder criteria. Conclusion Our findings underscore the multi-modal nature of ‘response’, show that many responders experience residual symptoms post-biologic-initiation, and that predictors of response vary according to outcome assessed. Keywords: anti-IgE; anti-IL5/5R; anti-IL4Rα; control; exacerbation; lung function; oral corticosteroid | en_US |
| dc.description.abstract | BACKGROUND: Biologic effectiveness is often assessed as 'response', a term which eludes consistent definition. Identifying those most likely to respond in real-life has proven challenging. OBJECTIVE: To explore definitions of biologic responders in adults with severe asthma and investigate patient characteristics associated with biologic response. METHODS: This was a longitudinal cohort study using data from 21 countries, which shared data with the International Severe Asthma Registry. Changes in 4 asthma outcome domains were assessed in the 1-year period pre- and post-biologic-initiation in patients with predefined level of pre-biologic impairment. Responder cut-offs were: ≥50% reduction in exacerbation rate, ≥50% reduction in long-term oral corticosteroid [LTOCS] daily dose, ≥1 category improvement in asthma control, and ≥100mL improvement in FEV1. Responders were defined using single- and multiple-domains. The association between pre-biologic characteristics and post-biologic-initiation response were examined by multivariable analysis. RESULTS: 2,210 patients were included. Responder rate ranged from 80.7% (n=566/701) for exacerbation-response to 10.6% (n=9/85) for 4-domain-response. Many responders still exhibited significant impairment post-biologic-initiation: 46.7% (n=206/441) of asthma control-responders with uncontrolled asthma pre-biologic still had incompletely-controlled disease post-biologic-initiation. Predictors of response were outcome-dependent. Lung function-responders were more likely to have higher pre-biologic FeNO (OR:1.20 for every 25ppb increase), and shorter asthma duration (OR:0.81, for every 10-year increase in duration). Higher BEC and presence of T2-related comorbidities were positively associated with higher odds of meeting LTOCS-, control- and lung function-responder criteria. CONCLUSION: Our findings underscore the multi-modal nature of 'response', show that many responders experience residual symptoms post-biologic-initiation, and that predictors of response vary according to outcome assessed. | en_US |
